relapsed or refractory multiple myeloma

Showing 1 - 25 of 45

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for

Completed
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Relapsed or Refractory Multiple Myeloma
  • BEBT-908 for injection
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Oct 9, 2023

Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Sep 20, 2023

Relapsed or Refractory Multiple Myeloma Trial (Cevostamab, Elranatamab, Tocilizumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jun 22, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 24, 2023

Relapsed or Refractory Multiple Myeloma Trial in Canada, United States (mRNA-2736)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • mRNA-2736
  • Birmingham, Alabama
  • +12 more
Jun 15, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • YTS104 Cells injection
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 13, 2023

Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Mar 6, 2023

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (JNJ-79635322)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Edegem, Belgium
  • +16 more
Jan 27, 2023

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (CC-92480, Carfilzomib, Dexamethasone)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Mobile, Alabama
  • +130 more
Jan 27, 2023

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Teclistamab, Pomalidomide, Bortezomib)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Berkeley, California
  • +188 more
Jan 27, 2023

Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)

Withdrawn
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jan 26, 2023

Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • STI-6129
  • Beijing, Beijing, China
  • +3 more
Jan 9, 2023

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Carfilzomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Fountain Valley, California
  • +107 more
Dec 7, 2022

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Pomalidomide)

Active, not recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Birmingham, Alabama
  • +45 more
Dec 6, 2022

Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • SVd (Selinexor+Bortezomib+dexamethasone)
  • Vd (Bortezomib+dexamethasone)
  • Hefei, Anhui, China
  • +33 more
Aug 14, 2022

Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Aug 12, 2022

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Daratumumab, Pomalidomide)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Tucson, Arizona
  • +191 more
Aug 11, 2022

Relapsed or Refractory Multiple Myeloma Trial in Dummy (Teclistamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • Dummy, France
  • +2 more
Aug 10, 2022

Relapsed or Refractory Multiple Myeloma Trial in Nagoya, Shibuya-ku (Elranatamab (PF-06863135))

Active, not recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Nagoya, Aichi, Japan
  • +1 more
Jun 20, 2022

Relapsed or Refractory Multiple Myeloma Trial in Germany, Spain, United States (INCB001158, Daratumumab SC)

Completed
  • Relapsed or Refractory Multiple Myeloma
  • Daphne, Alabama
  • +28 more
May 5, 2022

Relapsed or Refractory Multiple Myeloma Trial in Australia, China (EMB-06)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • EMB-06
  • Buderim, Queensland, Australia
  • +5 more
May 4, 2022

Relapsed or Refractory Multiple Myeloma Trial in United States (CAR2 Anti-CD38 A2 CAR-T Cells)

Completed
  • Relapsed or Refractory Multiple Myeloma
  • CAR2 Anti-CD38 A2 CAR-T Cells
  • Jacksonville, Florida
  • +3 more
Mar 14, 2022

Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia Trial in Worldwide (AMG 176, Azacitidine,

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Relapsed or Refractory Acute Myeloid Leukemia
  • AMG 176
  • +2 more
  • Duarte, California
  • +23 more
Feb 9, 2022

Relapsed or Refractory Multiple Myeloma Trial in West Hollywood, Rochester (ORIC-533)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • West Hollywood, California
  • +1 more
Feb 2, 2022

Relapsed or Refractory Multiple Myeloma Trial in Beijing (Mitoxantrone Hydrochloride Liposome injection, Bortezomib for

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Mitoxantrone Hydrochloride Liposome injection
  • +2 more
  • Beijing, Beijing, China
    Beijing Chaoyang Hospital, Capital Medical University
Jan 16, 2022